Psychedelics and sexual functioning: a mixed-methods study

Barba and colleagues begin by situating the research within the recent revival of clinical interest in classic psychedelics after decades of limited study. Earlier clinical and anecdotal work suggests that substances such as psilocybin can reduce depressive symptoms and improve wellbeing, and qualitative accounts have reported changes in sexual attitudes and experiences after psychedelic use. Sexual dysfunction is common in major depressive disorder (MDD) and is a frequent adverse effect of selective serotonin reuptake inhibitors (SSRIs), creating both quality-of-life and treatment-adherence concerns. Despite these converging lines of interest, the post‑acute effects of psychedelics on sexual functioning had not previously been tested quantitatively. The present paper set out to address that gap by combining data from two independent investigations with complementary designs: a large naturalistic prospective survey of people planning psychedelic experiences in community and ceremonial settings (Study 1), and a Phase II double‑blind randomised controlled trial (Study 2) that compared psilocybin therapy with the SSRI escitalopram in patients with MDD. The authors aimed to assess post‑acute changes in multiple domains of sexual functioning and satisfaction, and to compare effects between psilocybin and escitalopram within the RCT context. By bringing together observational and experimental data, they intended to provide an initial quantitative estimate of whether psychedelic use influences sexual wellbeing beyond acute drug effects.

Two distinct datasets were analysed. Study 1 combined two prospective online survey cohorts recruiting adults who planned to consume classic psychedelics either personally or in organised ceremonial settings. Participants completed baseline questionnaires one week before the planned experience, and follow‑ups at four weeks and six months. From the combined surveys, 1,463 completed baseline, 718 completed the four‑week assessment and 322 the six‑month follow‑up; 261 participants had the requisite baseline, four‑week and six‑month data used in the present analyses. The sample was predominantly white, majority employed full‑time, and mostly drawn from the United States. Study 2 used data from a Phase II double‑blind randomised controlled trial comparing two doses of active psilocybin therapy with an SSRI regimen. Fifty‑nine patients with moderate–severe MDD were randomised (30 to the psilocybin arm, 29 to the escitalopram arm) and analysed using an intention‑to‑treat approach. The psilocybin arm received two 25 mg doses of psilocybin plus daily placebo for six weeks; the comparator arm received two 1 mg control doses of psilocybin and daily escitalopram (10 mg for three weeks then 20 mg for three weeks). Both arms received the same psychological support model (an adapted Acceptance and Commitment Therapy format), with approximately 20 hours of in‑person therapeutic contact and additional integration calls. Some participants discontinued study medication or missed dosing days for reasons reported in the text. Outcome measures were harmonised across studies where possible. The primary sexual outcomes were selected items from the Brief Index of Sexual Functioning for Women (BISF‑W) adapted to be gender‑neutral: experienced pleasure, ability to communicate sexual desires, satisfaction with one's partner, perceived importance of sex, and body‑image satisfaction. Two investigator‑constructed items assessed openness to sexual exploration and perceiving sex as a spiritual experience. In the RCT, an additional retrospective BISF‑W item (item 13) assessed perceived pre/post changes in interest, arousal, activity, satisfaction and anxiety; the Psychotropic‑Related Sexual Dysfunction Questionnaire (PRSexDQ‑SALSEX) measured sexual dysfunction at the six‑week endpoint. Wellbeing was measured with the Flourishing Scale and depressive symptoms with the Quick Inventory of Depressive Symptomatology Self‑Report (QIDS‑SR‑16). Statistical approaches matched the data types: Study 1 used non‑parametric Friedman tests for within‑subject ordinal change over three timepoints, followed by Wilcoxon signed‑rank tests and Spearman correlations with flourishing. Cumulative link models (ordinal regression) examined sex differences. Study 2 used cumulative link mixed models with random intercepts to compare arms on ordinal BISF‑W items, post‑hoc contrasts from estimated marginal means, and Mann‑Whitney U tests for endpoint‑only measures (BISF‑W item 13 and PRSexDQ‑SALSEX). Bonferroni corrections were applied where indicated, and effect sizes appropriate for ordinal data were reported.

Study 1 (naturalistic surveys) showed statistically significant within‑participant changes across time for all sexual functioning items except perceived importance of sex. The largest changes were seen for viewing sex as a spiritual or sacred experience, satisfaction with one's appearance, satisfaction with one's partner, and experienced pleasure. Follow‑up tests indicated that scores at both four weeks and six months were elevated relative to baseline for these items. Spearman correlations with the Flourishing Scale found modest positive associations between improvements in wellbeing and changes in sexual communication (rho = 0.25, p = 0.001), appearance satisfaction (rho = 0.24, p = 0.0001), openness to sexual exploration (rho = 0.22, p < 0.001), and seeing sex as spiritual (rho = 0.17, p < 0.01); correlations for partner satisfaction and pleasure did not reach corrected significance. Study 2 (RCT) produced convergent but more specific findings. Cumulative link model post‑hoc contrasts revealed psilocybin‑specific improvements in partner satisfaction, communication with partner, and perceiving sex as spiritual; appearance satisfaction improved in both psilocybin and escitalopram arms. In the psilocybin group, experienced pleasure during sexual activity increased significantly from baseline (ΔEMM = 1.30, z = 3.10, p = 0.0019), an effect the authors described as equivalent to a 32.5% greater frequency of pleasurable sexual experiences compared with baseline. Retrospective BISF‑W item 13 at six weeks indicated that patients receiving psilocybin were significantly more likely than those receiving escitalopram to report increases in sexual interest (p = 0.0002), arousal (p = 0.0004), activity (p = 0.0007), and satisfaction (p = 0.0006); by contrast, the escitalopram group on average reported reductions in these domains. Sexual anxiety decreased in the psilocybin arm and increased in the escitalopram arm, though the between‑group difference for anxiety reached significance only before multiple‑comparison correction (p = 0.028). On the PRSexDQ‑SALSEX measure of sexual dysfunction at six weeks, severity differed markedly between arms. In the escitalopram arm 8 patients were classed as severe, 6 moderate, 3 mild and 12 none; in the psilocybin arm 1 severe, 3 moderate and 26 none. A Mann‑Whitney U test showed significantly higher sexual dysfunction severity in the escitalopram group (U = 255.5, p = 0.001; means: escitalopram M = 1.3, SD = 1.3; psilocybin M = 0.3, SD = 0.8). When collapsing both RCT arms, increases in sexual arousal and interest correlated moderately with improvements in depressive symptoms (arousal rho = 0.38, p < 0.01; interest rho = 0.36, p < 0.01). Correlations of depression change with sexual satisfaction, activity and anxiety did not survive correction for multiple comparisons.

Barba and colleagues interpret their convergent findings from an observational cohort and an RCT as preliminary empirical evidence that psychedelic use—and psilocybin therapy in particular—may produce post‑acute improvements in multiple domains of sexual functioning and satisfaction. They highlight consistent signals across very different populations and settings: community users reported sustained increases in pleasure, partner communication, partner satisfaction, body‑image satisfaction, openness to sexual novelty and a greater tendency to view sex as spiritual; depressed patients receiving psilocybin therapy showed improvements in several of the same domains, whereas patients treated with escitalopram did not, and in some cases reported worsening. The authors situate these differences within pharmacological and psychological frameworks. They note that SSRI mechanisms—elevating synaptic serotonin—are commonly implicated in sexual dysfunction, possibly via downstream effects on dopamine, testosterone and other mediators, and by emotional blunting. Psilocybin acts primarily as a 5‑HT2A receptor agonist, and although the acute effects of 5‑HT2A agonism on sexual behaviour are incompletely understood, the investigators emphasise that their results concern post‑acute changes rather than in‑the‑moment drug‑sex effects. They speculate that durable improvements in mindfulness, interpersonal connectedness, emotional processing and reductions in rumination following psychedelic experience could plausibly mediate enhanced sexual wellbeing, and that changes in attachment security after psilocybin therapy might also contribute, though these mechanisms were not directly tested. Limitations are addressed at length. The survey study used selected items from the BISF‑W rather than full validated scales, introduced two unvalidated items (sexual openness, sex as spiritual), and is subject to self‑selection, sampling, attrition and lack of experimental control, limiting causal inference. The RCT offers experimental control but differs in population and context from the survey cohorts, and both arms received substantial psychological support which may have synergised with drug effects. The authors caution that antidepressant withdrawal prior to psilocybin dosing could confound results for some participants, that the sample was demographically homogenous (predominantly white, heterosexual, employed and well educated), and that safety concerns exist regarding sexually abusive behaviour in some psychedelic contexts. They therefore recommend replication using more comprehensive and validated sexual measures, dyadic assessments involving partners, more diverse samples, and further work to disentangle pharmacological versus psychological contributors to the observed effects. Overall, the investigators present these data as early quantitative evidence that psychedelics can be associated with improved sexual functioning post‑acutely, and they call for more targeted research to confirm, clarify mechanisms, and define clinical implications. They refrain from extending claims beyond the data and underscore the need for ethical safeguards as policies and clinical practice evolve.

Barba and colleagues conclude that their combined observational and randomised data provide preliminary evidence that psychedelic use—and psilocybin therapy in particular—may improve several facets of post‑acute sexual functioning and satisfaction, including experienced pleasure, sexual communication, partner and body‑image satisfaction. In contrast, escitalopram was associated with greater sexual dysfunction in this trial despite similar reductions in depressive symptoms. The authors recommend further research using comprehensive validated instruments, diverse samples, and designs capable of elucidating mechanisms before clinical or policy conclusions are drawn.